DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Meitheal Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa
04/11/2025
Industria
Salud
Higiene alimentaria
VIH, SIDA y enfermedades autoinmunes
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Meitheal Pharmaceuticals Receives Approval from the US Food and Drug Administration for CONTEPO™ (fosfomycin) for injection in Patients ≥ 18 Years Having Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP)
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/10/2025
Eventos
Industria
Salud
Higiene alimentaria
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Farmacéutica
Biotecnología
Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
31/07/2025
Biotecnología
Farmacéutica
Salud
Mercado laboral
Industria
Meitheal Pharmaceuticals Announces Appointment of Dr. Keith Robinson as Chief Medical Officer and Expansion of Medical Affairs Operation
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/05/2025
Biotecnología
Salud
Farmacéutica
Material médico sanitario
Oncología
Mercado laboral
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/04/2025
Industria
Ciencia
Sanidad
Farmacéutica
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
Meitheal Pharmaceuticals Announces Approval and Launch of Liraglutide Injection in the United States
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
11/12/2024
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Mercado laboral
Industria
Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for XENLETA® (lefamulin acetate)
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
31/10/2024
Mercado laboral
Biotecnología
Sanidad
Farmacéutica
Salud
Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S.
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/07/2024
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
Mercado de valores
Industria
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
27/06/2024
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®
Fuente
Meitheal Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0